Merial Acquires Legend, Marquis from Bayer
Edited Press Release
March 2, 2015
Merial acquired Marquis (15% w/w ponazuril), used to treat EPM, and joint therapy product Legend (hyaluronate sodium).
Merial acquired Marquis (15% w/w ponazuril), used to treat EPM, and joint therapy product Legend (hyaluronate sodium).
North America Thoroughbred stakeholders respond to the British Horseracing Authority’s new Equine Anti-Doping Rules.
A comparison of triamcinolone and a triamcinolone/hyaluronic acid combo yielded “unexpected” results, researchers said.
Legislation governing racehorse medication policy passed the Florida Senate Regulated Industries Committee Feb. 18.
Dr. Nancy Loving offers information about storing medications during the winter.
Legislation governing equine medication policy is scheduled to be heard Feb. 18.
A number of samples from Thoroughbred racehorses recently came back positive for anabolic steroids.
The sales company will begin implementing guidelines for controlled therapeutic medications this spring.
The RCI intends to take the lead role in gathering the information needed to set racehorse medication policies.
The colt’s bloodwork showed the presence of altrenogest, a product typically used to regulate mares’ estrous cycles.
The policy says racehorses must not be given anabolic steroids. Positive tests will result in a 12-month training ban.
Officials are looking into a report that a yearling sold at a recent auction has tested positive for anabolic steroids.
Three trainers received suspensions and fines in conjunction with positive stanozolol tests.
The new trimethoprim sulfadiazine (TMS) formulation reduced fever and eliminated infection in many treated horses.
Researchers found that ceftiofur did not penetrate the placenta effectively, making it a poor placentitis treatment.
Officials will hear from groups involved in an effort to have all racing jurisdictions adopt uniform drug policies.
Stay on top of the most recent Horse Health news with
